Literature DB >> 30569216

Inhibition of periarticular bone loss is associated with clinical remission and ACR70-Response in rheumatoid arthritis.

Alexander Pfeil1, Anica Nussbaum2, Diane M Renz3, Christian Jung4, Peter Oelzner2, Ansgar Malich5, Gunter Wolf2, Joachim Böttcher6.   

Abstract

The aim of this study, based on a post hoc analysis of the data set used in the RAPID 1 trial, focuses on the associations between metacarpal bone mineral density, as estimated by digital X-ray radiogrammetry (DXR), and clinical remission as well as ACR70-Response in rheumatoid arthritis (RA) patients treated with certolizumab pegol (CZP). The trial evaluates a total of 345 RA patients treated with methotrexate versus CZP 200 mg versus CZP 400 mg. All patients underwent X-rays of the hand at baseline and week 52 as well as computerized calculations of bone mineral density (BMD) by DXR. Clinical remission was defined as DAS28 < 2.6. ACR70-Response was also evaluated. The radiological assessment of disease progression was estimated using the modified total Sharp Score. The mean difference for DAS28 was observed for patients treated with CZP 400 mg (median: - 3.53, minimum: - 6.77; maximum: + 0.48) and CZP 200 mg (median: - 3.13, minimum: - 6.37; maximum: - 0.52) compared to the methotrexate group (median - 2.41, minimum: - 4.76; maximum: + 0.31). The DXR-BMD showed a minor bone loss for the treatment groups undergoing therapy with CZP 200 mg (median: - 0.009 g/cm2, minimum: - 0.059 g/cm2; maximum: + 0.095 g/cm2) and CZP 400 mg (median: - 0.008 g/cm2, minimum: - 0.064 g/cm2; maximum: + 0.080 g/cm2). The methotrexate group presented an advanced periarticular metacarpal bone loss as measured by DXR-BMD (median: - 0.024 g/cm2, minimum: - 0.102 g/cm2; maximum: + 0.057 g/cm2). In the case of clinical remission and ACR70-Response, no significant change of the DXR-BMD was observed for both CZP groups. The study highlights that patients treated with CZP show a less accentuated periarticular bone loss as estimated by DXR in comparison to patients with methotrexate plus placebo. In addition, patients with clinical remission and ACR70-Response revealed no periarticular demineralisation.

Entities:  

Keywords:  ACR70-Response; Bone mineral density; Certolizumab pegol; Clinical remission; Digital X-ray radiogrammetry; Rheumatoid arthritis

Mesh:

Substances:

Year:  2018        PMID: 30569216     DOI: 10.1007/s00296-018-4226-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  33 in total

1.  Estimation of bone mineral density by digital X-ray radiogrammetry: theoretical background and clinical testing.

Authors:  A Rosholm; L Hyldstrup; L Backsgaard; M Grunkin; H H Thodberg
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

2.  Computerized quantification of joint space narrowing and periarticular demineralization in patients with rheumatoid arthritis based on digital x-ray radiogrammetry.

Authors:  Joachim Böttcher; Alexander Pfeil; Anders Rosholm; Peter Sörös; Alexander Petrovitch; Max L Schaefer; Bettina E Seidl; Ansgar Malich; Andreas Hansch; Gunter Wolf; Werner A Kaiser
Journal:  Invest Radiol       Date:  2006-01       Impact factor: 6.016

3.  Peripheral bone status in rheumatoid arthritis evaluated by digital X-ray radiogrammetry and compared with multisite quantitative ultrasound.

Authors:  J Böttcher; A Pfeil; H Mentzel; A Kramer; M-L Schäfer; G Lehmann; T Eidner; A Petrovitch; A Malich; G Hein; W A Kaiser
Journal:  Calcif Tissue Int       Date:  2006-01-06       Impact factor: 4.333

4.  Value of digital X-ray radiogrammetry in the assessment of inflammatory bone loss in rheumatoid arthritis.

Authors:  Alexander Pfeil; Glenn Haugeberg; Andreas Hansch; Diane M Renz; Gabriele Lehmann; Ansgar Malich; Gunter Wolf; Joachim Böttcher
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-05       Impact factor: 4.794

5.  From inhibition of radiographic progression to maintaining structural integrity: a methodological framework for radiographic progression in rheumatoid arthritis and psoriatic arthritis clinical trials.

Authors:  Robert Landewé; Vibeke Strand; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-04-25       Impact factor: 19.103

6.  Digital X-ray radiogrammetry in the study of osteoporotic fractures: Comparison to dual energy X-ray absorptiometry and FRAX.

Authors:  Johan Kälvesten; Li-Yung Lui; Torkel Brismar; Steven Cummings
Journal:  Bone       Date:  2016-02-24       Impact factor: 4.398

Review 7.  Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.

Authors:  L C Hofbauer; A E Heufelder
Journal:  J Mol Med (Berl)       Date:  2001-06       Impact factor: 4.599

8.  Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study.

Authors:  Charlotte L M Krieckaert; Michael T Nurmohamed; Gertjan Wolbink; Willem F Lems
Journal:  Rheumatology (Oxford)       Date:  2012-12-05       Impact factor: 7.580

9.  Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study.

Authors:  Pernille Bøyesen; Mari Hoff; Sigrid Odegård; Glenn Haugeberg; Silje W Syversen; Per I Gaarder; Cecilie Okkenhaug; Tore K Kvien
Journal:  Arthritis Res Ther       Date:  2009-07-01       Impact factor: 5.156

10.  Hand bone loss as an outcome measure in established rheumatoid arthritis: 2-year observational study comparing cortical and total bone loss.

Authors:  Mari Hoff; Glenn Haugeberg; Tore K Kvien
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more
  2 in total

1.  Bone erosion in the 2nd metacarpophalangeal head: association with its bone mineral density by HR-pQCT in rheumatoid arthritis patients.

Authors:  Camille P Figueiredo; Mariana O Perez; Lucas Peixoto Sales; Ana Cristina Medeiros; Valeria F Caparbo; Rosa M R Pereira
Journal:  BMC Musculoskelet Disord       Date:  2021-01-25       Impact factor: 2.362

2.  Radiographic remission in rheumatoid arthritis quantified by computer-aided joint space analysis (CASJA): a post hoc analysis of the RAPID 1 trial.

Authors:  Alexander Pfeil; Anica Nussbaum; Diane M Renz; Tobias Hoffmann; Ansgar Malich; Marcus Franz; Peter Oelzner; Gunter Wolf; Joachim Böttcher
Journal:  Arthritis Res Ther       Date:  2020-10-06       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.